To ensure the homogeneity of the group, individuals with two KRAS mutations (n = 2, OS 155 and 186 days) and one patient who was additionally diagnosed with a second type of cancer (rectal cancer, OS 122 days) were excluded. This evidence concerns the gene KRAS and cancer.